AORT
Artivion, Inc.
AORT's outlook is improving, though it still trails on the overall score.
UNH
UnitedHealth Group Incorporated
UNH has the edge over AORT overall, supported by lower modeled downside and stronger modeled upside.
AORT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Weak |
AORT's revenue is currently stable, but its profitability, cash flow and balance sheet are under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
AORT PE Valuation
AORT has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
AORT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for AORT, with profitability holding steady.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
AORT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.05 | — |
| Q3 2026 | -$0.35 | -$0.10 |
| Q2 2026 | -$0.06 | +$0.37 |
| Q1 2026 | $0.25 | +$0.76 |
| Q4 2025 | $0.21 | +$0.53 |
| Q3 2025 | -$0.25 | -$0.23 |
| Q2 2025 | -$0.43 | -$0.22 |
| Q1 2025 | -$0.51 | -$0.27 |
| Q4 2024 | -$0.32 | +$0.43 |
AORT is still losing money, but far less than before: $0.35 per share over the past year, against $1.03 at its worst in late 2022.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over AORT on earnings quality, reporting a profit while its opponent remains loss making.
AORT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $123.8M | +9.2% |
| Q2 2026 | $125.8M | +11% |
| Q1 2026 | $116.3M | +18% |
| Q4 2025 | $116M | +19% |
| Q3 2025 | $113.4M | +18% |
| Q2 2025 | $113M | +15% |
| Q1 2025 | $99M | +1.6% |
| Q4 2024 | $97.3M | +3.9% |
AORT has the edge over UNH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.4% | -8.7 points |
| Q2 2026 | -6.7% | -14 points |
| Q1 2026 | 5% | +2.8 points |
| Q4 2025 | 9.2% | +6.5 points |
| Q3 2025 | 11% | +6.5 points |
| Q2 2025 | 7.4% | +0.8 points |
| Q1 2025 | 2.2% | -24 points |
| Q4 2024 | 2.7% | -0.6 points |
AORT's operating margin was 2.4% last quarter, down 8.7 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over AORT on profitability, with a higher operating margin.
AORT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$17.6M | -200% |
| Q2 2026 | -$12M | -202% |
| Q1 2026 | -$6.8M | +$13.7M |
| Q4 2025 | -$7.9M | -191% |
| Q3 2025 | $17.7M | +126% |
| Q2 2025 | $11.7M | +224% |
| Q1 2025 | -$20.6M | -$11.5M |
| Q4 2024 | $8.7M | -2.2% |
AORT's free cash flow was −$44M over the past year, against $18M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over AORT on cash generation, producing positive trailing cash flow while its opponent burns cash.
AORT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +177K shares |
| 1 year | -0.1% | -57K shares |
| 3 years | +19% | +7.8M shares |
| 5 years | +9.6% | +4.3M shares |
| Available history | +29% | +10.9M shares |
AORT has 49M diluted shares, about the same as a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over AORT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
AORT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 8.5x | High |
| Q2 2026 | 6.3x | High |
| Q1 2026 | 2.6x | Moderate |
| Q4 2025 | 2.7x | Moderate |
| Q3 2025 | 2.9x | Moderate |
| Q2 2025 | 4.0x | Elevated |
| Q1 2025 | 7.0x | High |
| Q4 2024 | 4.1x | High |
AORT's net debt is about 8.5 years of its operating earnings (EBITDA), up from 2.9 years a year ago.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH has the edge over AORT on leverage, with a lower net debt burden relative to earnings.
AORT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.0 | Neutral |
| Stochastic | 10.1 | Oversold |
AORT's weekly RSI is 31 (neutral) and its Stochastic is 10 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
AORT PE vs Healthcare Sector
| Metric | AORT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
AORT has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
AORT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.7 | 11% below |
| 20 week MA | $24.2 | 20% below |
| 50 week MA | $30.8 | 37% below |
| 100 week MA | $32.0 | 39% below |
| 200 week MA | $25.7 | 24% below |
AORT is in a downtrend: it's below all five of its weekly moving averages, and 24% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over AORT on trend strength, trading above more of its moving averages.
AORT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $26.7 | $23.5 | -12% |
| 2021 | $23.5 | $20.4 | -14% |
| 2022 | $20.4 | $11.8 | -42% |
| 2023 | $11.8 | $17.9 | +51% |
| 2024 | $17.9 | $29.0 | +62% |
| 2025 | $29.0 | $46.3 | +60% |
| 2026 YTD | $46.3 | $19.4 | -58% |
AORT has finished lower in three of the last six years. It's down 58% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over AORT on returns for 2026, with the stronger performance.